Celularity Inc. Form 8-K Summary
Reporting date: March 13, 2024; filed March 15, 2024. The filing reports material financing, registration, forbearance and warrant transactions. It does not provide quarterly or annual operating results.
Business Context and Reporting Period
Celularity entered into financing arrangements intended to provide working capital and general corporate funding. The company is an emerging growth company, and its Class A common stock trades on Nasdaq under the symbol CELU.
Financing, Debt and Liquidity
- Standby Equity Purchase Agreement: Celularity may sell up to $10.0 million of Class A common stock to YA II PN, Ltd. (Yorkville) over 36 months, subject to conditions and Nasdaq limitations. Sales are generally at 97% of the lowest applicable three-day VWAP.
- Initial advance: Yorkville provided $2.99 million in cash after a 5% original issue discount in exchange for a $3.15 million convertible promissory note. The note bears interest at 8.0%, increasing to 18.0% upon specified defaults, and matures March 13, 2025.
- Conversion terms: The initial conversion price is $6.3171 per share, subject to a reset based on market prices on the earlier of the fifth trading day after resale registration becomes effective or August 13, 2024. The reset price is subject to a $2.4898 floor.
- Issuance limitations: Shares issuable under the note and SEPA are capped at 19.9% of outstanding common stock as of March 13, 2024. Yorkville is subject to a 4.99% beneficial ownership blocker.
- Fees: Celularity paid Yorkville a $25,000 due diligence fee and issued 16,964 commitment-fee shares.
- Other lender arrangements: Celularity agreed to increase interest rates on its Resorts World Inc. (RWI) and C.V. Starr & Co. loans by 100 basis points.
Material Changes, Outlook and Risks
- The SEPA provides potential additional capital, but proceeds depend on the frequency and prices of future stock sales; Celularity may receive no additional proceeds beyond the initial advance.
- Yorkville cannot request advances or convert the initial note until the SEC declares effective a resale registration statement. Celularity agreed to file that statement by May 3, 2024 and use commercially reasonable efforts to obtain effectiveness within 45 days of filing.
- RWI agreed to forbear from exercising default remedies until the Yorkville note is indefeasibly paid in full or March 13, 2025, whichever occurs first. Starr agreed to similar forbearance until the Yorkville note is indefeasibly paid in full.
- Celularity issued RWI a warrant for up to 300,000 shares, expiring June 20, 2028, with a $5.895 exercise price.
- Starr warrant exercise prices for warrants covering 75,000 and 50,000 shares were amended to $5.895 per share.
- The transactions may result in interest expense, dilution and additional equity issuance. Defaults under the Yorkville note could accelerate repayment of principal and accrued interest.
- Proceeds are expected to be used for working capital and general corporate purposes.
Operating Metrics
The filing text does not provide clear values for revenue, net income or loss, cash flow, cash and equivalents, liquidity runway, debt balances other than the Yorkville note, or operating margins. No new management guidance was reported.
Important Facts for Investors to Verify
- Whether the resale registration statement was filed by May 3, 2024 and when it became effective.
- The amount and pricing of any subsequent Yorkville advances or note conversions.
- Celularity’s total debt, cash balance, interest obligations and ability to repay the $3.15 million note at maturity.
- The potential dilution from SEPA shares, note conversion, commitment-fee shares and RWI and Starr warrants.
- Compliance with the 19.9% Nasdaq issuance cap and Yorkville’s 4.99% ownership limitation.
- Whether any defaults occurred under the Yorkville, RWI or Starr agreements and whether the related forbearance protections remained in effect.